Latest news with #USFood&DrugAdministration
Time of India
12-06-2025
- Business
- Time of India
The AI inflection point: Why every CXO must act now
In 1999, internet pioneer Vint Cerf equated a single year in the digital world to seven in the real one. Today, artificial intelligence has made even that dizzying pace look AI isn't just another buzzword—it's a potent mix of data, computing muscle, rapid investment, and relentless user growth, accelerating far beyond previous technological leaps. If it feels like change has never come faster, that's because it hasn't. And the numbers back that up. Here are some insights from Mary Meeker's whopping 340 page 'AI Trends Report': Rapid Adoption: The New NormalRemember Tom Cruise's iconic "need for speed" from Top Gun? Consider this: ChatGPT took just 17 months to hit 800 million weekly users, compared to the internet's 23 years to reach similar global ecosystems are booming too. Google's Gemini platform alone saw a staggering five-fold growth in its developer base in a single year. But this surge isn't mere consumer fascination. Enterprises and governments are scaling AI in critical areas—operations, customer engagement, R&D, and even regulatory frameworks. Case in point: The US Food & Drug Administration (FDA) is pushing for complete AI integration across all departments by mid-2025. CXO Takeaway: Rapid adoption means CXOs must proactively integrate AI into core business strategies—not just dabble on the sidelines. Quick experiments and swift deployments are no longer optional, they're survival imperatives. Spending Surges, Monetization Lags Last year, the Big Six tech giants (Apple, NVIDIA, Microsoft, Alphabet, AWS, and Meta) spent a whopping $212 billion on infrastructure—up 63% YoY—mostly directed at AI. Yet, the financial returns aren't matching the investment fervor. OpenAI illustrates this vividly: it generated $3.7 billion last year but spent $5 billion just maintaining operations. Such economics are common in early tech cycles—expensive to build, unclear monetization paths, yet bursting with potential. However, the rapidly declining cost of deploying AI models hints at an imminent inflection. True value might soon shift from the models themselves to the innovative products and business models built atop them. CXO Takeaway: Investment is necessary, but monetization and strategic patience are crucial. CXOs should carefully balance short-term financial realities against the long-term transformative potential of AI-driven initiatives. The New Global Battleground Competition is heating up—and fast. Open-source AI, especially from China, is rapidly closing gaps, with Alibaba's Qwen2.5-Max surpassing GPT-4o and Claude 3.5 on certain performance benchmarks. This race is no longer merely commercial; it's geopolitical. As Mary Meeker's report warns, "AI leadership could beget geopolitical leadership—and not vice versa." CXO Takeaway: CXOs must consider AI not just as a competitive advantage, but as a strategic imperative influencing geopolitical positioning, partnerships, and risk management. Real-World Impact: AI Moves Off Screens AI is swiftly transitioning from digital experimentation to tangible, physical impact. Autonomous taxis now constitute 34% of San Francisco's ride bookings. Kaiser Permanente's doctors have already leveraged AI scribes over 2.5 million times, dramatically reducing paperwork. Yum! Brands, the parent company behind KFC and Pizza Hut, has deployed AI across 25,000 outlets to rethink operations fundamentally. CXO Takeaway: CXOs must now envision AI beyond traditional digitization—rethinking workflows, physical operations, and customer interactions from the ground up. Your People Strategy Is Your AI Strategy AI-related job postings surged by 448%, while non-AI roles fell 9%. This dramatic shift isn't just about hiring—it's a critical leadership imperative for retraining, reorienting, and realigning workforce capabilities. Despite heavy AI spending, adoption remains uneven. A Morgan Stanley survey from 2024, cited in the Meeker report, reveals that although 75% of CMOs are exploring AI, most implementations remain incremental, not transformative. Further underscoring the strategic gap, only half of the S&P 500 companies mention AI during earnings calls—suggesting a significant disconnect at the board level. Even when companies adopt AI, the tendency to limit usage to superficial applications persists. The highest returns come only when businesses fundamentally redesign workflows, reshape teams, and recenter strategies around AI. CXO Takeaway: CXOs must spearhead a deeper cultural and operational shift toward AI-centric thinking. This means investing heavily in training, restructuring teams for AI readiness, and embedding AI into board-level strategy discussions—not treating it as a technology afterthought. In a Nutshell: AI is redefining the rules of speed, strategy, and global competition. For CXOs, this isn't a future scenario—it's happening now. Those who embrace these insights and act decisively will shape their industries; those who delay risk becoming case studies in disruption.
&w=3840&q=100)
Business Standard
23-05-2025
- Business
- Business Standard
Alembic Pharma receives USFDA approval for generic hypertension drug
Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of amlodipine and atorvastatin tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement. These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added. Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
23-05-2025
- Business
- Time of India
Alembic Pharma gets USFDA nod for generic high blood pressure treatment drug
Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of amlodipine and atorvastatin tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement. These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added. Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA.
Metro
15-05-2025
- Health
- Metro
Urgent recall of soups, rice and porridge over 'life-threatening' risk in US
More than a dozen varieties of soup, rice and porridge mixes have been recalled in the US for containing three undeclared allergens. NatureMills US Inc is recalling 17 of its items sold nationwide because they contain wheat, milk and sesame, which were not listed in the labels. The company based in Prosper, Texas, announced on Tuesday that 'people who have an allergy or severe sensitivity to these allergens run the risk of serious or life-threatening allergic reactions if they consume these products'. NatureMills rice mixes under the recall include the Idly Chilli Powder, Sesame Rice Mix, Dal Garlic Rice Mix, Moringa Rice Mix, Curry Leaf Rice Mix, Vallarai Rice Mix and Horsegram Rice Mix. Its affected soups are the Wonderberry Leaf Soup, Moringa Leaf Soup, Avarampoo Soup and Horsegram Soup. Spice mixes and powders that are recalled include the Traditional Sambar Powder and the Traditional Rasam Powder. The company's Black Kavuni Porridge Mix, as well as its Garlic Vadam, Tomato Vadam and Rice Papad, are also recalled. More Trending NatureMills issued the recall after a routine audit found that the three ingredients were missing from the labels. 'The issue was the result of a oversight in the packaging process,' stated the notice from the US Food & Drug Administration (FDA), which is responsible for protecting public health across the nation. 'Immediate corrective measures have been implemented.' Consumers with allergies to the ingredients are advised to throw away the products and contact NatureMills for a replacement or full refund. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: History of Air Force One as Trump eyes accepting $400,000,000 Qatari plane MORE: Brain dead woman Adriana Smith forced to be kept alive due to draconian US law MORE: Trump's health secretary says people shouldn't take 'medical advice from me'
Business Upturn
15-05-2025
- Business
- Business Upturn
Alembic Pharma gets USFDA nod for Rivaroxaban tablets across four strengths; to launch 2.5 mg in Q1 FY26
By Aditya Bhagchandani Published on May 15, 2025, 13:42 IST Alembic Pharmaceuticals Limited announced on May 15 that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths. These tablets are therapeutically equivalent to Xarelto, a product marketed by Janssen Pharmaceuticals, Inc., and are used to reduce the risk of major cardiovascular and thrombotic vascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). The company plans to launch the 2.5 mg strength in the first quarter of FY26. According to IQVIA, the estimated market size for the 2.5 mg dosage in the U.S. is $445 million for the 12 months ending March 2025, while the market size for the 10 mg, 15 mg, and 20 mg strengths collectively stands at $8,052 million. With this approval, Alembic now holds a cumulative total of 222 ANDA approvals, which includes 198 final approvals and 24 tentative approvals from the USFDA. Alembic Pharmaceuticals, headquartered in Vadodara, India, is a vertically integrated pharmaceutical company engaged in manufacturing and marketing of generic drugs globally. The company has over 5,200 field personnel and a well-established brand presence in the Indian generics market. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
